Clinical Trial Update: A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 study of Pegilodecakin (LY3500518) in patients with advanced solid tumors has completed, spanning multiple indications including melanoma, prostate canc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Colorectal Cancer
• Melanoma
• Non-small Cell Lung Cancer
• Ovarian Cancer
• Pancreatic Cancer
• Prostate Cancer
• Renal Cell Carcinoma

Drugs mentioned

• Pegilodecakin (pegilodecakin)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Melanoma, Prostate Cancer | Phase 1 | Status: COMPLETED